Enhanced antitumor efficacy on hepatoma-bearing rats with adriamycin-loaded nanoparticles administered into hepatic artery.
OBJECTIVE
To investigate the antitumor activity of adriamycin (ADR) encapsulated in nanoparticles (NADR) and injected into the hepatic artery of hepatoma-bearing rats.


METHODS
NADR was prepared by the interfacial polymerization method. Walker-256 carcinosarcomas were surgically implanted into the left liver lobes of 60 male Wistar rats, which were divided into 4 groups at random (15 rats per group). On the 7th day after implantation, normal saline (NS), free ADR (FADR), NADR, or ADR mixed with unloaded nanoparticles (ADR+NP) was respectively injected via the hepatic artery (i.a.) of rats in different groups. The dose of ADR in each formulation was 2.0 mg/kg body weight and the concentration was 1.0 mg/mL. Survival time, tumor enlargement ratio, and tumor necrosis degree were compared between each group.


RESULTS
Compared with the rats that received NS i.a., the rats that received FADR or ADR+NP acquired apparent inhibition on tumor growth, as well as prolonged their life span. Further significant anticancer efficacy was observed in rats that received i.a. administration of NADR. Statistics indicated that NADR brought on a more significant tumor inhibition and more extensive tumor necrosis, as compared to FADR or ADR+NP. The mean tumor enlargement ratio on the 7th day after NADR i.a. was 1.106. The mean tumor-bearing survival time was 39.50 days. Prolonged life span ratio was 109.22% as compared with rats that accepted NS.


CONCLUSIONS
Therapeutic effect of ADR on liver malignancy can be significantly enhanced by its nanopaticle formulation and administration via hepatic artery.
Chen
Jiang-Hao
JH
Department of Vascular and Endocrine Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710033, Shaanxi Province, China. chenjh@fmmu.edu.cn
Ling
Rui
R
Yao
Qing
Q
Wang
Ling
L
Ma
Zhong
Z
Li
Yu
Y
Wang
Zhe
Z
Xu
Hu
H
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D002279:Carcinoma 256, Walker / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D004317:Doxorubicin / Q000494:pharmacology*; D006499:Hepatic Artery; D007269:Injections, Intra-Arterial; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D036103:Nanotechnology; D009336:Necrosis; D010316:Particle Size; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D016019:Survival Analysis
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin